All About Multiple Sclerosis

More MS news articles for November 2003

An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients

Neurology. 2003 Nov 25;61(10):1444-6
Pachner AR.
Department of Neurology and Neurosciences, UMDNJ-New Jersey Medical School, Newark.

A reliable screening assay for anti-interferon beta (IFNbeta) antibodies is needed for patients with multiple sclerosis (MS) receiving IFNbeta therapy.

The performance of a new ELISA method, the capture ELISA (cELISA), was assessed by comparing it to a standard IFNbeta ELISA in correlating with neutralizing antibodies measurement in 453 sera from patients with MS.

The cELISA outperformed the standard ELISA, and may be a suitable screening assay for anti-IFNbeta antibodies in IFNbeta-treated patients with MS.